Tranexamic Acid for Gastrointestinal Bleeding
Do not use high-dose intravenous tranexamic acid (1g loading dose followed by 3g over 24 hours) for acute gastrointestinal bleeding, as it does not reduce mortality or bleeding but increases thromboembolic complications. 1
Evidence Against High-Dose TXA
The definitive HALT-IT trial (2020), which randomized 12,009 patients with acute GI bleeding, demonstrated that high-dose extended infusion TXA:
- Did not reduce death from bleeding (4% in both TXA and placebo groups, RR 0.99,95% CI 0.82-1.18) 1
- Did not reduce rebleeding rates 1
- Increased venous thromboembolic events (0.8% vs 0.4%, RR 1.85,95% CI 1.15-2.98), including deep vein thrombosis and pulmonary embolism 1
- Also increased seizure risk (RR 1.73) 2
This high-quality, large-scale trial supersedes earlier meta-analyses that suggested potential mortality benefit, which were based on small, methodologically limited studies conducted before modern endoscopic therapy and proton pump inhibitor use became standard 3, 4.
Current Guideline Recommendations
British Society of Gastroenterology (2019) recommends confining tranexamic acid use in acute lower GI bleeding to clinical trials only, noting that earlier studies showing mortality benefit were conducted before routine high-dose acid suppression and endoscopic therapy, making their extrapolation to modern care uncertain 3. The International Consensus Group guidelines (2019) for upper GI bleeding do not recommend tranexamic acid, instead focusing on endoscopic therapy and proton pump inhibitors as primary treatments 3.
Low-Dose TXA: Insufficient Evidence
While some meta-analyses suggest low-dose IV or enteral TXA may reduce rebleeding (RR 0.5) and need for surgery (RR 0.58) with moderate certainty evidence 2, there is insufficient safety data to recommend this approach outside of clinical trials. The risk-benefit profile remains unclear.
What Actually Works for GI Bleeding
Focus on evidence-based interventions that do improve outcomes:
- Early endoscopy within 24 hours for upper GI bleeding 3
- Endoscopic hemostatic therapy for high-risk stigmata (active bleeding or visible vessel) using thermocoagulation, sclerosant injection, or clips 3
- High-dose PPI therapy: IV loading dose followed by continuous infusion for bleeding ulcers with high-risk stigmata after successful endoscopic therapy 3
- Interventional radiology for ongoing bleeding when endoscopic therapy fails or is unavailable 3
Common Pitfall to Avoid
Do not extrapolate TXA's proven benefits in trauma and postpartum hemorrhage to GI bleeding—the pathophysiology and treatment context differ substantially, and the HALT-IT trial definitively showed no benefit with increased harm 1.